Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to 15.91%.

  • Ani Pharmaceuticals' EBITDA Margin rose 297400.0% to 15.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.7%, marking a year-over-year increase of 66000.0%. This contributed to the annual value of 1.3% for FY2024, which is 98900.0% down from last year.
  • Ani Pharmaceuticals' EBITDA Margin amounted to 15.91% in Q3 2025, which was up 297400.0% from 6.57% recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' EBITDA Margin peaked at 27.19% during Q1 2021, and registered a low of 38.94% during Q4 2021.
  • For the 5-year period, Ani Pharmaceuticals' EBITDA Margin averaged around 1.32%, with its median value being 3.74% (2024).
  • The largest annual percentage gain for Ani Pharmaceuticals' EBITDA Margin in the last 5 years was 408700bps (2022), contrasted with its biggest fall of -569600bps (2022).
  • Over the past 5 years, Ani Pharmaceuticals' EBITDA Margin (Quarter) stood at 38.94% in 2021, then surged by 105bps to 1.93% in 2022, then soared by 165bps to 5.11% in 2023, then tumbled by -145bps to 2.3% in 2024, then skyrocketed by 792bps to 15.91% in 2025.
  • Its last three reported values are 15.91% in Q3 2025, 6.57% for Q2 2025, and 13.29% during Q1 2025.